Fintel on MSN1d
Morgan Stanley Initiates Coverage of Celldex Therapeutics (CLDX) with Overweight RecommendationFintel reports that on March 20, 2025, Morgan Stanley initiated coverage of Celldex Therapeutics (NasdaqCM:CLDX) with a ...
Analysts have recently evaluated Morgan Stanley and provided 12-month price targets. The average target is $140.3, ...
Morgan Stanley MS.N toned down its emphasis on diversity in its latest annual report published on Friday, signaling a recalibration as businesses adapt to a changing reality under President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback